“…There is a scope for 39 compounds which can be developed as future antimycobacterial drugs. 24,26,33,61,62,65,68,69,83,85,86,[95][96][97][98][116][117][118][119][120]123, and 125-127, with MICs < 10 µg/mL, are comparable to antimycobacterial agents such as INH, RMP, and EMB, and may become future potential antimycobacterial drugs. Compounds 9, 49, 84, and 124, which act as efflux pump inhibitors, may be useful in reversing drug resistance to TB caused by MDR forms.…”